- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03078036
International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study (BREAKOUT)
BREAKOUT -International Breast Cancer Biomarker, Standard of Care and Real World Outcomes Study
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
Queensland
-
Redcliffe, Queensland, Australien
- Research Site
-
-
South Australia
-
Kurralta Park, South Australia, Australien
- Research Site
-
-
Victoria
-
Ballarat, Victoria, Australien
- Research Site
-
-
-
-
-
Dobrich, Bulgarien
- Research Site
-
Ruse, Bulgarien
- Research Site
-
Sofia, Bulgarien
- Research Site
-
-
-
-
-
Tubingen, Deutschland
- Research Site
-
-
-
-
-
Milano, Italien
- Research Site
-
Pavia, Italien
- Research Site
-
Reggio Emilia, Italien
- Research Site
-
-
Modena
-
Carpi, Modena, Italien
- Research Site
-
-
Varese
-
Castellanza, Varese, Italien
- Research Site
-
-
-
-
Chiba-Ken
-
Kamogawa-shi, Chiba-Ken, Japan
- Research Site
-
-
Ehime-Ken
-
Matsuyama-shi, Ehime-Ken, Japan
- Research Site
-
-
Fukuoka-Ken
-
Fukuoka-shi, Fukuoka-Ken, Japan
- Research Site
-
-
Hokkaido
-
Sapporo-shi, Hokkaido, Japan
- Research Site
-
-
Miyagi-Ken
-
Sendai-shi, Miyagi-Ken, Japan
- Research Site
-
-
Osaka-Fu
-
Osaka-shi, Osaka-Fu, Japan
- Research Site
-
-
Tokyo-To
-
Chuo-ku, Tokyo-To, Japan
- Research Site
-
-
-
-
-
Quebec, Kanada, G1S 4L8
- Research Site
-
-
Ontario
-
Kingston, Ontario, Kanada, K7L 5P9
- Research Site
-
Kitchener, Ontario, Kanada, N2G 1G3
- Research Site
-
-
Quebec
-
Chicoutimi, Quebec, Kanada, G7H 5H6
- Research Site
-
-
-
-
-
Busan, Korea, Republik von
- Research Site
-
Seoul, Korea, Republik von
- Research Site
-
Ulsan, Korea, Republik von
- Research Site
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Korea, Republik von
- Research Site
-
Seongnam-si, Gyeonggi-do, Korea, Republik von
- Research Site
-
Seongnam-si,, Gyeonggi-do, Korea, Republik von
- Research Site
-
-
-
-
-
Brzozow, Polen
- Research Site
-
Opole, Polen
- Research Site
-
Walbrzych, Polen
- Research Site
-
Warszawa, Polen
- Research Site
-
Wieliszew, Polen
- Research Site
-
Wroclaw, Polen
- Research Site
-
Zory, Polen
- Research Site
-
-
-
-
-
Chelyabinsk, Russische Föderation
- Research Site
-
Krasnodar, Russische Föderation
- Research Site
-
Novosibirsk, Russische Föderation
- Research Site
-
Omsk, Russische Föderation
- Research Site
-
Pyatigorsk, Russische Föderation
- Research Site
-
Ryazan, Russische Föderation
- Research Site
-
Tomsk, Russische Föderation
- Research Site
-
-
-
-
-
Barcelona, Spanien
- Research Site
-
Burgos, Spanien
- Research Site
-
Girona, Spanien
- Research Site
-
Huelva, Spanien
- Research Site
-
-
Barcelona
-
Terrassa, Barcelona, Spanien
- Research Site
-
-
La Coruña
-
A Coruna, La Coruña, Spanien
- Research Site
-
-
Madrid
-
Alcorcon, Madrid, Spanien
- Research Site
-
San Sebastian de los Reyes, Madrid, Spanien
- Research Site
-
-
-
-
-
Changhua, Taiwan
- Research Site
-
Kaohsiung, Taiwan
- Research Site
-
Taichung, Taiwan
- Research Site
-
Tainan, Taiwan
- Research Site
-
Taipei, Taiwan
- Research Site
-
-
-
-
-
Adana, Truthahn
- Research Site
-
Ankara, Truthahn
- Research Site
-
Antalya, Truthahn
- Research Site
-
Diyarbakir, Truthahn
- Research Site
-
Istanbul, Truthahn
- Research Site
-
Izmir, Truthahn
- Research Site
-
Kocaeli, Truthahn
- Research Site
-
Sakarya, Truthahn
- Research Site
-
Samsun, Truthahn
- Research Site
-
Tekirdag, Truthahn
- Research Site
-
Trabzon, Truthahn
- Research Site
-
Van, Truthahn
- Research Site
-
-
-
-
-
Budapest, Ungarn
- Research Site
-
Szeged, Ungarn
- Research Site
-
Szekszard, Ungarn
- Research Site
-
Szolnok, Ungarn
- Research Site
-
-
-
-
California
-
Santa Barbara, California, Vereinigte Staaten, 93105
- Research Site
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten, 80218
- Research Site
-
-
Florida
-
Hialeah, Florida, Vereinigte Staaten, 33012
- Research Site
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75246
- Research Site
-
Denton, Texas, Vereinigte Staaten, 76210
- Research Site
-
Flower Mound, Texas, Vereinigte Staaten, 75028
- Research Site
-
Houston, Texas, Vereinigte Staaten, 77024
- Research Site
-
Houston, Texas, Vereinigte Staaten, 77089
- Research Site
-
Paris, Texas, Vereinigte Staaten, 75460
- Research Site
-
San Antonio, Texas, Vereinigte Staaten, 78217
- Research Site
-
The Woodlands, Texas, Vereinigte Staaten, 77380
- Research Site
-
-
Virginia
-
Newport News, Virginia, Vereinigte Staaten, 23601
- Research Site
-
-
Washington
-
Vancouver, Washington, Vereinigte Staaten, 98684
- Research Site
-
Wenatchee, Washington, Vereinigte Staaten, 98801
- Research Site
-
-
-
-
Cambridgeshire
-
Huntingdon, Cambridgeshire, Vereinigtes Königreich
- Research Site
-
Peterborough, Cambridgeshire, Vereinigtes Königreich
- Research Site
-
-
Cornwall
-
Truro, Cornwall, Vereinigtes Königreich
- Research Site
-
-
Derbyshire
-
Derby, Derbyshire, Vereinigtes Königreich
- Research Site
-
-
Devon
-
Exeter, Devon, Vereinigtes Königreich
- Research Site
-
-
East Sussex
-
Worthing, East Sussex, Vereinigtes Königreich
- Research Site
-
-
Greater London
-
London, Greater London, Vereinigtes Königreich
- Research Site
-
-
Lancashire
-
Blackpool, Lancashire, Vereinigtes Königreich
- Research Site
-
Lancaster, Lancashire, Vereinigtes Königreich
- Research Site
-
-
Staffordshire
-
Stoke on Trent, Staffordshire, Vereinigtes Königreich
- Research Site
-
-
Warwickshire
-
Warwick, Warwickshire, Vereinigtes Königreich
- Research Site
-
-
West Midlands
-
Wolverhampton, West Midlands, Vereinigtes Königreich
- Research Site
-
-
West Yorkshire
-
Huddersfield, West Yorkshire, Vereinigtes Königreich
- Research Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Provision of signed, written and dated informed consent.
- Adult females (according to the age of majority/adulthood as defined by local regulations).
- Histologically or cytologically confirmed HER2-ve breast cancer with evidence of metastatic disease.
- Initiated treatment with 1st line systemic cytotoxic chemotherapy (not hormonal therapy) for metastatic breast cancer in the last 90 days and, at that time, are considered to have exhausted hormone therapy options (if HR+ve).
Exclusion Criteria:
- Previous enrolment in this study.
- Involvement in the planning and/or conduct of this study (applies to both AstraZeneca staff and/or staff at the study site).
- Current participation in a clinical study with an investigational oncology product.
- Previous PARPi therapy, including, but not limited to, participation in a previous clinical study that included PARPi therapy.
- Current commencement of PARPi treatment.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
Observation
Human epidermal growth factor receptor 2 negative metastic breast cancer patients who have started 1st line systemic cytotoxic chemotheraphy and are considered to have exhausted hormone therapy options (if HR+ve), per investigator's opinion.
|
If unavailable from the patient medical records, gBRCA gene mutation status will be tested as aligned to local clinical practice using a blood sample obtained preferably during routine clinical practice.
(Note: Blood samples may be shipped to a central laboratory for testing and storage, based on local regulations for shipment of blood samples.)
Archival tumour specimen will be requested from all patients in the informed consent, but is not required for study enrolment (optional consent). Where sufficient archival tumour specimen is available and patients have consented to tumour specimen testing, FoundationOne Dx genomic profiling may take place as follows:
Patients who test positive for a gBRCA gene mutation, and/or sBRCA or other HRR gene mutations (optional testing), will be followed prospectively for assessment of treatment patterns and associated clinical outcomes up to 30-months. - Patients who test negative for gBRCA gene mutations, sBRCA and other HRR gene mutations, no further data will be collected post baseline. Patients presenting other genomic alterations that are identified by the FoundationOne Dx genomic profile will not continue beyond baseline as part of this study. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
BRCA Mutational status (BRCA1 mutated and/or BRCA2 mutated or BRCA wild type).
Zeitfenster: At one time point at inclusion in the study up to 12 months after the beginning of the study.
|
The prevalence of gBRCA gene mutations will be evaluated by calculating the proportion of patients that test positive for a gBRCA gene mutation (BRCA1 mutated and/or BRCA2 mutated).
|
At one time point at inclusion in the study up to 12 months after the beginning of the study.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Descriptive statistics for treatments administered by line of therapy from 1st line metastatic breast cancer.
Zeitfenster: 2.5 years (30 months) since the beginning of the study.
|
Treatment patterns will be described by line of therapy.
Treatment combinations, number of cycles per line, schedules, durations, and reason for discontinuation will be summarized descriptively.
|
2.5 years (30 months) since the beginning of the study.
|
Progression free survival by line of therapy
Zeitfenster: 2.5 years (30 months) since the beginning of the study.
|
Progression free survival (in months) for each line of treatment, defined as the time from the date of start of each line of treatment to the documented date of progression as determined by the investigator (radiologic or symptomatic), or death from any cause in the absence of progression.
|
2.5 years (30 months) since the beginning of the study.
|
Overall survival by line of therapy
Zeitfenster: 2.5 years (30 months) since the beginning of the study.
|
Overall survival (OS) defined as the time from the start date of first line chemotherapy in the metastatic setting until the date of death due to any cause, assessed up to 30 months.
In addition, OS since diagnosis of metastatic breast cancer and OS since the start of each subsequent therapy will be estimated.
|
2.5 years (30 months) since the beginning of the study.
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Koh SJ, Ohsumi S, Takahashi M, Fukuma E, Jung KH, Ishida T, Dai MS, Chang CH, Dalvi T, Walker G, Bennett J, O'Shaughnessy J, Balmana J. Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study. Breast Cancer. 2022 Jan;29(1):92-102. doi: 10.1007/s12282-021-01283-4. Epub 2021 Aug 31. Erratum In: Breast Cancer. 2021 Sep 25;:
- O'Shaughnessy J, Brezden-Masley C, Cazzaniga M, Dalvi T, Walker G, Bennett J, Ohsumi S. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. Breast Cancer Res. 2020 Oct 27;22(1):114. doi: 10.1186/s13058-020-01349-9.
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- D0816R00012
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Brustkrebs
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
Klinische Studien zur Germline BRCA Test (blood)
-
ANRS, Emerging Infectious DiseasesInstitute of Research for Development, FranceAbgeschlossen
-
University of Southern CaliforniaNational Cancer Institute (NCI)Noch keine RekrutierungDreifach negativer BrustkrebsVereinigte Staaten